- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03892564
Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream
February 11, 2020 updated by: MC2 Therapeutics
A 4-Day, Randomized Study to Evaluate the Potential of MC2-01 Cream to Induce a Phototoxicity Skin Reaction in Healthy Subjects, Using a Controlled Photopatch Test Design
This trial is a 4-day, randomized study to determine the phototoxic potential of MC2-01 Cream when topical application to healthy skin is followed by light exposure.
Study Overview
Status
Completed
Conditions
Detailed Description
This study evaluates the potential of MC2-01 (CAL/BDP 0.005/0.042w/w%)
Cream to cause a phototoxic reaction using a controlled photopatch test design.
Because MC2-01 Cream is formulated for topical use and have shown to absorb light, it is necessary to determine the potential of this product to cause a phototoxic reaction after topical application and irradiation of the skin.
Study Type
Interventional
Enrollment (Actual)
35
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
Fair Lawn, New Jersey, United States, 07410
- TKL Research Inc
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Is a healthy male or female
- Is 18 years of age or older
- Agree not to participate in any clinical or patch test studies at Day 1 through study completion
- Females of childbearing potential must use a highly effective method of contraception for one month prior to Screening and until the end of study visit has been performed
- in the case of a female of childbearing potential, has a negative urine pregnancy test on Day 1 prior to randomization and are willing to submit to a urine pregnancy test at the end of study
- In the case of a female of non-childbearing potential, has had a hysterectomy or is postmenopausal
- Is free of any systemic or dermatological disorder, which, in the opinion of the Investigator, will interfere with the study results or increase the risk of AEs.
- Has uniformly-colored skin on the intrascapular region of the back which will allow discernment of erythema, and has Fitzpatrick skin types I, II or III
- Complete a medical screening procedure
- Read, understand and sign an informed consent
Exclusion Criteria:
- Has a history of photosensitivity or photoallergy
- Has any visible skin disease at the application site which, in the opinion of the Investigator, will interfere with the evaluation of the test site reaction
- Current or past history of hypercalcemia, vitamin D toxicity, severe renal insufficiency or severe hepatic disorders
- Is using systemic/topical corticosteroids within 3 weeks prior to and/or during the study or systemic/topical antihistamines 72 hours prior to and during the study
- Is not willing to refrain from using systemic/topical anti-inflammatory analgesics (81 mg aspirin and occasional use of acetaminophen will be permitted)
- Are taking medication known to cause phototoxic reaction
- Is using medication which, in the opinion of the Investigator, will interfere with the study results
- Is unwilling or unable to refrain from the use of sunscreens, cosmetics, creams, ointments, lotions or similar products on the back during the study
- Has psoriasis and/or atopic dermatitis/eczema
- Has a known sensitivity or allergy to constituents of the materials being evaluated
- Is a female who is pregnant, plans to become pregnant during the study, or is breast feeding a child
- Has damaged skin in or around the test sites, including sunburn, excessively deep tans, uneven skin tones, tattoos, scars excessive hair, numerous freckles or other disfigurations of the test site
- Has received treatment for any type of internal cancer within 5 years prior to study entry
- Has a history of, or are currently being treated for skin cancer and/or hepatitis
- Has a history or, or is currently being treated for diabetes
- Has any condition that might compromise study results
- Is expected to sunbathe or use tanning salons during the study
- Has a history of adverse response to UV-sun lamps/sunlight exposure
- Is currently participating in any clinical testing
- Has any known sensitivity to adhesives
- Has received any investigational drug(s) within 28 days from Day 1
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: MC2-01 Cream, irradiation
One applications with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%)
cream, followed by irradiation
|
One application of MC2-01 Cream, followed by irradiation.
Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
|
EXPERIMENTAL: MC2-01 Cream, no irradiation
One application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%),
no irradiation.
Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
|
One application of MC2-01 Cream.
Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
|
EXPERIMENTAL: MC2-01 vehicle, irradiation
One application of MC2-01 vehicle, followed by irradiation.
Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
|
One application of MC2-01 vehicle, followed by irradiation.
Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
|
EXPERIMENTAL: MC2-01 vehicle, no irradiation
One application of MC2-01 vehicle, no irradiation.
Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
|
One application of MC2-01 vehicle.
Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
|
EXPERIMENTAL: Control, irradiation
Untreated, irradiated site.
Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
|
Untreated, irradiated site.
Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Within-subject Comparison and Evaluator Rating of Possible Dermal Reactions (Erythema, Edema and Other Signs of Cutaneous Irritation), After Application of MC2-01 Cream, MC2-01 Vehicle or Untreated at Defined Test Sites, Followed by Irradiation
Time Frame: Baseline, before irradiation
|
MC2-01 Cream, MC2-01 vehicle will be applied each to two sites.
One further site will function as control site and will remain untreated.
24 hours after product application, the test sites, including the untreated control site will be evaluated for cutaneous reaction.
One set of MC2-01 and MC2-01 vehicle + the untreated control site will be designated for irradiation and the other set will remain non-irradiated.
Possible changes in dermal reactions (erythema, edema and other signs of cutaneous irritation) at the 5 test sites, 24 and 48 hours post-irradiation is the outcome measure of the study
|
Baseline, before irradiation
|
Within-subject Comparison and Evaluator Rating of Possible Dermal Reactions (Erythema, Edema and Other Signs of Cutaneous Irritation), After Application of MC2-01 Cream, MC2-01 Vehicle or Untreated at Defined Test Sites, Followed by Irradiation
Time Frame: 24h post-irradiation
|
MC2-01 Cream, MC2-01 vehicle will be applied each to two sites.
One further site will function as control site and will remain untreated.
24 hours after product application, the test sites, including the untreated control site will be evaluated for cutaneous reaction.
One set of MC2-01 and MC2-01 vehicle + the untreated control site will be designated for irradiation and the other set will remain non-irradiated.
Possible changes in dermal reactions (erythema, edema and other signs of cutaneous irritation) at the 5 test sites, 24 and 48 hours post-irradiation is the outcome measure of the study
|
24h post-irradiation
|
Within-subject Comparison and Evaluator Rating of Possible Dermal Reactions (Erythema, Edema and Other Signs of Cutaneous Irritation), After Application of MC2-01 Cream, MC2-01 Vehicle or Untreated at Defined Test Sites, Followed by Irradiation
Time Frame: 48h post-irradiation
|
MC2-01 Cream, MC2-01 vehicle will be applied each to two sites.
One further site will function as control site and will remain untreated.
24 hours after product application, the test sites, including the untreated control site will be evaluated for cutaneous reaction.
One set of MC2-01 and MC2-01 vehicle + the untreated control site will be designated for irradiation and the other set will remain non-irradiated.
Possible changes in dermal reactions (erythema, edema and other signs of cutaneous irritation) at the 5 test sites, 24 and 48 hours post-irradiation is the outcome measure of the study
|
48h post-irradiation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jonathan S Dorsik, TKL Research, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
February 27, 2019
Primary Completion (ACTUAL)
March 9, 2019
Study Completion (ACTUAL)
March 9, 2019
Study Registration Dates
First Submitted
March 20, 2019
First Submitted That Met QC Criteria
March 25, 2019
First Posted (ACTUAL)
March 27, 2019
Study Record Updates
Last Update Posted (ACTUAL)
February 12, 2020
Last Update Submitted That Met QC Criteria
February 11, 2020
Last Verified
February 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MC2-01-C9
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Single site study
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Phototoxicity
-
Michele SayagCompleted
-
LEO PharmaQuintiles, Inc.Completed
-
PharmaEssentiaPharmaEssentia Japan K.K.Completed
Clinical Trials on MC2-01 Cream, irradiation
-
MC2 TherapeuticsCompletedPhotoallergyUnited States
-
MC2 TherapeuticsRecruitingEfficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS) (Orchid 1)Vulvar Lichen SclerosusDenmark
-
MC2 TherapeuticsRecruitingChronic Kidney Disease-associated PruritusUnited Kingdom
-
MC2 TherapeuticsTerminatedPsoriasis VulgarisCzechia, Germany
-
MC2 TherapeuticsCompleted
-
MC2 TherapeuticsCompleted
-
MC2 TherapeuticsCompletedPsoriasis VulgarisUnited States
-
Cassiopea SpACompletedAcne VulgarisUnited States, Georgia, Ukraine
-
Cassiopea SpACompletedAcne VulgarisUnited States, Bulgaria, Georgia, Poland, Romania, Serbia
-
aRigen Pharmaceuticals, Inc.UnknownHerpes Zoster | Postherpetic NeuralgiaUnited States